Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Market Closed 03-21 16:00:00 EDT

0.8637

-0.0096

-1.10%

盘后0.8403

-0.0234-2.71%

18:34 EDT

High0.8700	Low0.8232	Vol1.41M
Open0.8545	D1 Closing0.8733	Amplitude5.36%
Mkt Cap160.74M	Tradable Cap150.09M	Total Shares186.10M
T/O1.20M	T/O Rate0.81%	Tradable Shares173.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":0.8637,"timestamp":1742587200000,"preClose":0.8733,"halted":0,"volume":1406664,"hourTrading":{"tag":"盘后","latestPrice":0.8403,"preClose":0.8637,"latestTime":"18:34 EDT","volume":59238,"amount":51158.4871,"timestamp":1742596469006},"delay":0,"floatShares":173771433,"shares":186103588,"eps":-0.578432,"marketStatus":"Market Closed","change":-0.0096,"latestTime":"03-21 16:00:00 EDT","open":0.8545,"high":0.87,"low":0.8232,"amount":1200482.0835336,"amplitude":0.05359,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.578432,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742803200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.8733,"preHourTrading":{"tag":"盘前","latestPrice":0.863,"preClose":0.8733,"latestTime":"09:29 EDT","volume":900,"amount":776.7,"timestamp":1742563770999},"postHourTrading":{"tag":"盘后","latestPrice":0.8403,"preClose":0.8637,"latestTime":"18:34 EDT","volume":59238,"amount":51158.4871,"timestamp":1742596469006},"volumeRatio":0.9749306053909477,"impliedVol":1.772,"impliedVolPercentile":0.824},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2521240001","title":"Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil","url":"https://stock-news.laohu8.com/highlight/detail?id=2521240001","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521240001?lang=en_us&edition=full_marsco","pubTime":"2025-03-23 06:57","pubTimestamp":1742684279,"startTime":"0","endTime":"0","summary":"The S&P 500 is down 8.6% in a month while the Nasdaq has lost nearly 13%. Markets continue to scare retail investors as stock after stock struggles to deal with the aftermath of Donald Trump’s unpredictable and aggressive policies.While it is advisable to stay out of the market till the dust settles, one also can’t deny that it is times like these that bring opportunities. We decided to come up with a list of stocks that are expected to go up even in the existing gloomy environment.To come up with the list of 10 stocks that Wall Street is bullish on, we looked at stocks that were recently upgraded by analysts and have performed well in the last 5 days of trading.A scientist in lab coat testing a new biopharmaceutical drug on a microscope.Nektar Therapeutics  operates as a biopharmaceutical company that discovers and develops therapies to treat autoimmune disorders. Its products include NKTR-358, PEG-CSF1, and others. The company’s stock price gained 6% in the previous year despite a do","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-nktr-among-stocks-225759230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","QLD","BK4007","SQQQ","TSYW.SI",".IXIC","QID","NKTR","USJW.SI","MNQmain","NQmain","PSQ","NVIW.SI","TQQQ"],"gpt_icon":1},{"id":"2519336624","title":"Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2519336624","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519336624?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 02:53","pubTimestamp":1741978384,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  shares were up more than 9% in recent Friday trading after Oppenheimer upgraded the company's stock to outperform from market perform, with a price target of $6.Trading volume was above 1.8 million shares against a daily average of roughly 2 million.Price: 0.89, Change: +0.07, Percent Change: +9.09","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR","OPY"],"gpt_icon":0},{"id":"2519806237","title":"Nektar Therapeutics Raised to Outperform From Perform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2519806237","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519806237?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 20:39","pubTimestamp":1741955940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 08:39 ET (12:39 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","OPY"],"gpt_icon":0},{"id":"2519731805","title":"Nektar Therapeutics : Oppenheimer Raises to Outperform From Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=2519731805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519731805?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 20:27","pubTimestamp":1741955268,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nAZN3K7COM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2519480112","title":"Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)","url":"https://stock-news.laohu8.com/highlight/detail?id=2519480112","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519480112?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:33","pubTimestamp":1741951980,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.38%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.23 per share when it actually produced a loss of $0.18, delivering a surprise of 21.74%.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-nktr-q4-earnings-113300417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKTR"],"gpt_icon":1},{"id":"2519787710","title":"Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6","url":"https://stock-news.laohu8.com/highlight/detail?id=2519787710","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519787710?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 19:20","pubTimestamp":1741951225,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has an average rating of overweight and mean price target of $4.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","NKTR"],"gpt_icon":0},{"id":"2519380578","title":"Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2519380578","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519380578?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 18:23","pubTimestamp":1741947790,"startTime":"0","endTime":"0","summary":"NasdaqCM:NKTR Revenue and Expenses Breakdown March 14th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 7.1%. Earnings per share  exceeded analyst estimates by 21%.In the last 12 months, the only revenue segment was Applying Our Technology Platform to Develop Novel Drug Candidates contributing US$98.4m. The largest operating expense was Research & Development (R&D) costs, amounting to US$120.9m . Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$11.0m. Explore how NKTR's revenue and expenses shape its earnings.Looking ahead, revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 5.3% from a week ago.We should say that we've discovered 4 warning signs for Nektar Therapeutics (1 can't be ignored!) that you should be aware of before investing here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-full-2024-earnings-102310714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKTR"],"gpt_icon":0},{"id":"2519570628","title":"Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2519570628","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519570628?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 00:15","pubTimestamp":1741882500,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 13 cents. In the year-ago quarter, the company had incurred a loss of 22 cents per share.See the ZacksEarnings Calendarto stay ahead of market-making news.Total revenues in the fourth quarter increased 22.2% year over year to $29.2 million. The reported figure however missed the Zacks Consensus Estimate of $39 million.In the past year, shares of Nektar have lost 4.7% compared with the industry’s decline of 8.7%.In the fourth quarter, product sales increased around 134.7% year over year to $12.9 million. Product sales beat the Zacks Consensus Estimate of $9.8 million as well as our model estimate of $10.4 million.Non-cash royalty revenues were $16.2 million, down around 10.5% from the year-ago quarter. However, the reported figure beat the Zacks Consensus Estimate of $15.2 million as well as our model estimate of $13.7 million.Resea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-q4-loss-wider-expected-161500904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109391861.USD","LU0114720955.EUR","LU0238689110.USD","LU0320765992.SGD","LU0106261372.USD","SG9999014914.USD","SGXZ31699556.SGD","ANIP","IE0004445239.USD","LU0943347566.SGD","LU0079474960.USD","LU0471298694.HKD","LU2361044949.HKD","LU0058720904.USD","LU1069344957.HKD","LU2461242641.AUD","LU0708995401.HKD","LU2089984988.USD","NKTR","LU1267930730.SGD","LU0006306889.USD","LU2491050154.USD","LU1127390331.HKD","LU1814569148.SGD","LU1868836757.USD","LU1989771016.USD","LU1291159041.SGD","LU0354030511.USD","JAZZ","LU0823416689.USD","LU1093756168.USD","LU2324357040.USD","SG9999014898.SGD","LU1366192091.USD","LU0882574139.USD","LU0122379950.USD","SG9999014906.USD","IE00BJT1NW94.SGD","LU2063271972.USD","IE0002141913.USD","SGXZ81514606.USD","IE00BK4W5M84.HKD","LU1720051108.HKD","LU1974910355.USD","SGXZ57979304.SGD","SG9999015945.SGD","LU0672654240.SGD","IE0009355771.USD","LU1023059063.AUD"],"gpt_icon":1},{"id":"2519511708","title":"Q4 2024 Nektar Therapeutics Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2519511708","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519511708?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 00:06","pubTimestamp":1741881978,"startTime":"0","endTime":"0","summary":"Vivian Wu; Associate Director, Investor Relations and Corporate Affairs; Nektar Therapeutics. Howard Robin; President, Chief Executive Officer, Director; Nektar Therapeutics. Brian Kotzin; Interim Chief Medical Officer; Nektar Therapeutics. Jonathan Zalevsky; Chief Research and Development Officer; Nektar Therapeutics. Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference call.  Please be advised that today's conference is being recorded. I would not like to hand the conference over to your speaker today. Vivian Wu. Please go ahead.Thank you, Vivian. Thank you all for joining us today. 2024 was a productive year for Nektar, and I'm very proud of our team for executing on important clinical development milestones for our lead autoimmune pipeline program, rezpegaldesleukin, also known as REZPEG. The achievement of these clinical development goals prepares us for meaningful data catalysts for REZPEG in 2025. Earlier thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-nektar-therapeutics-earnings-160618258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKTR"],"gpt_icon":0},{"id":"2519835095","title":"Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835095","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835095?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:14","pubTimestamp":1741868040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 08:14 ET (12:14 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2519154004","title":"William Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2519154004","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519154004?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 16:05","pubTimestamp":1741853124,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed yester...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-their-hold-rating-for-nektar-therapeutics-nktr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-their-hold-rating-for-nektar-therapeutics-nktr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR"],"gpt_icon":0},{"id":"2519507004","title":"Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2519507004","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519507004?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 15:09","pubTimestamp":1741849770,"startTime":"0","endTime":"0","summary":"Cash and Investments: $269.1 million at the end of 2024.Revenue: $29.2 million for Q4 2024; $98.4 million for the full year 2024.R&D Expenses: $28.7 million for Q4 2024; $120.9 million for the full year 2024.G&A Expenses: $17.1 million for Q4 2024; $76.8 million for the full year 2024.Net Income: $7.3 million for Q4 2024; net loss of $119 million for the full year 2024.Earnings Per Share: $0.03 basic and diluted for Q4 2024; $0.58 basic and diluted loss per share for the full year 2024.Gain from Sale: $40.4 million gain from the sale of the Huntsville manufacturing facility.2025 Revenue Guidance: Expected between $40 million and $50 million.2025 R&D Expense Guidance: Expected between $110 million and $120 million.2025 G&A Expense Guidance: Expected between $60 million and $65 million.Cash Runway: Expected to extend into Q4 2026.GuruFocus has detected 8 Warning Signs with NKTR.Nektar Therapeutics  has expanded its pre-clinical pipeline in immunology and inflammation, advancing its TNFR2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-nktr-q4-2024-070930354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKTR"],"gpt_icon":0},{"id":"2518788187","title":"Nektar Therapeutics  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518788187","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518788187?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:28","pubTimestamp":1741638487,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  expected to post a loss of17cents a share - Earnings Preview Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a rise in quarterly revenue when it reports  results on March 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT25M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":1},{"id":"2517859394","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517859394","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517859394?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 19:00","pubTimestamp":1741345200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Algonquin Pwr & Utl                              4Q       .09       BMO. ·Asana Inc. Class A                              4Q      (.01)  4:05 PM. ·Auna S.A. Class A                               4Q       .15       AMC. ·Vail Resorts Inc.                                2Q      6.29   4:05 PM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVEX","BNTX","SSP","MOMO","MYPS","CVGW","BW","AEO","VTS","CINT","TBRG","KRMD","ASRT","CIEN","HLLY","BTMD","ADBE","ATLC","ARCO","KALV","LE","DRRX","BDTX","CDTX","ORCL","NKTR","FTCI","LRMR","URGN","CING","DRUG","NOA","FERG","CHRS","ZVRA","LMB","AMRN","WEST","MGTX","AURA","BBCP","LEN.B","ACET","BWMN","SFIX","AUNA","EWCZ","DKS","GECC"],"gpt_icon":1},{"id":"2517197846","title":"Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2517197846","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517197846?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 07:00","pubTimestamp":1741215600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics  will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.To access the conference call, please pre-register atNektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-announce-financial-results-fourth-230000226.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-announce-financial-results-fourth-230000226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CSF","NKTR"],"gpt_icon":0},{"id":"2516622587","title":"Nektar Therapeutics  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622587?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:15","pubTimestamp":1741086910,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  expected to post a loss of17cents a share - Earnings Preview Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a rise in quarterly revenue when it reports  results on March 6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL5N3PN12H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2514334053","title":"Nektar Therapeutics  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514334053","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514334053?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:28","pubTimestamp":1740742086,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  expected to post a loss of17cents a share - Earnings Preview Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a rise in quarterly revenue when it reports  results on March 3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL5N3PJ0Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0},{"id":"2514395368","title":"Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Aa Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Severe-to-Very Severe Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2514395368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514395368?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:00","pubTimestamp":1740571223,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUADLLSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2514180839","title":"Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180839","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514180839?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics  today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.The REZOLVE-AA  study enrolled patients with severe-to-very-severe alopecia areata who have not received a JAK inhibitor or other biologic. Patients were randomized across two different dose regimens of rezpegaldesleukin or placebo. The primary efficacy endpoint will evaluate mean percent change in the Severity of Alopecia Tool  score at the end of the 36-week induction period. Secondary endpoints include proportion of participants with greater than or equal to 50% reduction in SALT score at week 36 and other assessed timepoints, mean percent improvement in SALT score at other assessed timepoints, and proportion of patients achieving SALT-20 .Enrollment criteria in the study included a diagnosis of severe-to-very-severe alopecia areata  as measured using ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000330.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4153","AA","NKTR","BK4585","BK4588","CSF","BK4007"],"gpt_icon":0},{"id":"2514093793","title":"Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514093793","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514093793?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 20:23","pubTimestamp":1740486180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 07:23 ET (12:23 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0369},{"period":"1month","weight":-0.1363},{"period":"3month","weight":-0.0696},{"period":"6month","weight":-0.3356},{"period":"1year","weight":-0.0374},{"period":"ytd","weight":-0.0713}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.548387,"avgChangeRate":0.042868},{"month":2,"riseRate":0.516129,"avgChangeRate":0.003089},{"month":3,"riseRate":0.419355,"avgChangeRate":0.005003},{"month":4,"riseRate":0.433333,"avgChangeRate":0.006304},{"month":5,"riseRate":0.366667,"avgChangeRate":0.006185},{"month":6,"riseRate":0.387097,"avgChangeRate":-0.018715},{"month":7,"riseRate":0.451613,"avgChangeRate":-0.014995},{"month":8,"riseRate":0.451613,"avgChangeRate":0.034164},{"month":9,"riseRate":0.483871,"avgChangeRate":0.014638},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.028591},{"month":11,"riseRate":0.677419,"avgChangeRate":0.089799},{"month":12,"riseRate":0.612903,"avgChangeRate":0.027386}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction